genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more
genedrive plc (GDR) - Net Assets
Latest net assets as of June 2025: GBX1.44 Million GBX
Based on the latest financial reports, genedrive plc (GDR) has net assets worth GBX1.44 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX2.81 Million) and total liabilities (GBX1.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.44 Million |
| % of Total Assets | 51.08% |
| Annual Growth Rate | 1.44% |
| 5-Year Change | -59.97% |
| 10-Year Change | -61.68% |
| Growth Volatility | 80.88 |
genedrive plc - Net Assets Trend (2006–2025)
This chart illustrates how genedrive plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for genedrive plc (2006–2025)
The table below shows the annual net assets of genedrive plc from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX1.44 Million | -73.17% |
| 2024-06-30 | GBX5.36 Million | +162.57% |
| 2023-06-30 | GBX2.04 Million | -63.63% |
| 2022-06-30 | GBX5.61 Million | +56.21% |
| 2021-06-30 | GBX3.59 Million | +207.48% |
| 2020-06-30 | GBX-3.34 Million | -34.87% |
| 2019-06-30 | GBX-2.48 Million | -1.68% |
| 2018-06-30 | GBX-2.44 Million | -170.82% |
| 2017-06-30 | GBX3.44 Million | -8.31% |
| 2016-06-30 | GBX3.75 Million | -60.68% |
| 2015-06-30 | GBX9.54 Million | -12.14% |
| 2014-06-30 | GBX10.86 Million | -9.88% |
| 2013-06-30 | GBX12.05 Million | +36.03% |
| 2012-06-30 | GBX8.86 Million | +43.35% |
| 2011-06-30 | GBX6.18 Million | +6.88% |
| 2010-06-30 | GBX5.78 Million | +109.57% |
| 2009-06-30 | GBX2.76 Million | +6.89% |
| 2008-06-30 | GBX2.58 Million | -0.58% |
| 2007-06-30 | GBX2.60 Million | +137.17% |
| 2006-06-30 | GBX1.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to genedrive plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6333500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX9.37 Million | 651.81% |
| Other Comprehensive Income | GBX2.50 Million | 173.99% |
| Other Components | GBX54.73 Million | 3806.26% |
| Total Equity | GBX1.44 Million | 100.00% |
genedrive plc Competitors by Market Cap
The table below lists competitors of genedrive plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NIGERIAN AVIATION HANDLING CO. PLC
XNSA:NAHCO
|
$1.10K |
|
Vindicator Silver-Lead Mining Co
PINK:VINS
|
$1.10K |
|
Trophy Resources Inc
PINK:TRSI
|
$1.10K |
|
Wejo Group Limited
PINK:WEJOF
|
$1.10K |
|
Petro Capital and Infrastructure Investment JSC
VN:PTL
|
$1.09K |
|
CUCKOO International (MAL) Berhad
KLSE:5336
|
$1.09K |
|
Science to Consumers Inc
PINK:BEUT
|
$1.09K |
|
Viet Nam Herbs and Foods JSC
VN:VHE
|
$1.09K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in genedrive plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,359,000 to 1,438,000, a change of -3,921,000 (-73.2%).
- Net loss of 5,231,000 reduced equity.
- New share issuances of 1,226,000 increased equity.
- Other comprehensive income increased equity by 2,502,000.
- Other factors decreased equity by 2,418,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.23 Million | -363.77% |
| Share Issuances | GBX1.23 Million | +85.26% |
| Other Comprehensive Income | GBX2.50 Million | +173.99% |
| Other Changes | GBX-2.42 Million | -168.15% |
| Total Change | GBX- | -73.17% |
Book Value vs Market Value Analysis
This analysis compares genedrive plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 401.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.77x to 401.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | GBX0.27 | GBX1.03 | x |
| 2007-06-30 | GBX0.56 | GBX1.03 | x |
| 2008-06-30 | GBX0.37 | GBX1.03 | x |
| 2009-06-30 | GBX0.35 | GBX1.03 | x |
| 2010-06-30 | GBX0.66 | GBX1.03 | x |
| 2011-06-30 | GBX0.69 | GBX1.03 | x |
| 2012-06-30 | GBX0.94 | GBX1.03 | x |
| 2013-06-30 | GBX1.30 | GBX1.03 | x |
| 2014-06-30 | GBX1.12 | GBX1.03 | x |
| 2015-06-30 | GBX0.95 | GBX1.03 | x |
| 2016-06-30 | GBX0.36 | GBX1.03 | x |
| 2017-06-30 | GBX0.19 | GBX1.03 | x |
| 2018-06-30 | GBX-0.13 | GBX1.03 | x |
| 2019-06-30 | GBX-0.09 | GBX1.03 | x |
| 2020-06-30 | GBX-0.09 | GBX1.03 | x |
| 2021-06-30 | GBX0.06 | GBX1.03 | x |
| 2022-06-30 | GBX0.07 | GBX1.03 | x |
| 2023-06-30 | GBX0.02 | GBX1.03 | x |
| 2024-06-30 | GBX0.03 | GBX1.03 | x |
| 2025-06-30 | GBX0.00 | GBX1.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently genedrive plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -363.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -684.69%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.96x
- Recent ROE (-363.77%) is below the historical average (-70.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -79.18% | -96.23% | 0.61x | 1.36x | GBX-976.50K |
| 2007 | -39.93% | -76.42% | 0.41x | 1.29x | GBX-1.30 Million |
| 2008 | -44.69% | -55.88% | 0.65x | 1.22x | GBX-1.41 Million |
| 2009 | 3.01% | 2.09% | 0.67x | 2.14x | GBX-193.00K |
| 2010 | 5.01% | 5.05% | 0.73x | 1.35x | GBX-288.40K |
| 2011 | 6.23% | 6.69% | 0.74x | 1.26x | GBX-233.20K |
| 2012 | -2.75% | -4.39% | 0.53x | 1.18x | GBX-1.13 Million |
| 2013 | -9.65% | -21.71% | 0.38x | 1.17x | GBX-2.37 Million |
| 2014 | -15.58% | -29.39% | 0.39x | 1.35x | GBX-2.78 Million |
| 2015 | -31.69% | -66.97% | 0.28x | 1.68x | GBX-3.98 Million |
| 2016 | -157.61% | -116.83% | 0.43x | 3.16x | GBX-6.29 Million |
| 2017 | -191.40% | -251.47% | 0.22x | 3.50x | GBX-6.93 Million |
| 2018 | 0.00% | -362.75% | 0.33x | 0.00x | GBX-6.79 Million |
| 2019 | 0.00% | -153.94% | 0.33x | 0.00x | GBX-3.39 Million |
| 2020 | 0.00% | -1833.71% | 0.10x | 0.00x | GBX-19.08 Million |
| 2021 | -19.24% | -100.58% | 0.14x | 1.36x | GBX-1.05 Million |
| 2022 | -83.32% | -9540.82% | 0.01x | 1.18x | GBX-5.24 Million |
| 2023 | -252.33% | -9363.64% | 0.01x | 2.21x | GBX-5.35 Million |
| 2024 | -132.02% | -1412.18% | 0.07x | 1.27x | GBX-7.61 Million |
| 2025 | -363.77% | -684.69% | 0.27x | 1.96x | GBX-5.37 Million |
Industry Comparison
This section compares genedrive plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $23,071,575
- Average return on equity (ROE) among peers: 11.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| genedrive plc (GDR) | GBX1.44 Million | -79.18% | 0.96x | $1.10K |
| Abingdon Health Plc (ABDX) | $5.81 Million | 59.68% | 0.19x | $1.83K |
| CelLBxHealth plc (CLBX) | $40.33 Million | -37.22% | 0.17x | $941.82 |